The present disclosure describes analog conotoxin peptides of the a-contoxin peptide RgIA. These analog conotoxin peptides block the a9a10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain, inflammatory conditions, inflammation, and/or cancer.